CLASS II Drug recall · Reported 8 Jun 2022 · FDA Enforcement Report

Losartan Pot./HCTZ 100/12.5 mg Packaged recalled by Direct Rx

Direct Rx is recalling Losartan Pot./HCTZ 100/12.5 mg Packaged, distributed in Alabama, Florida, Georgia, Louisiana. The recall was initiated on 5 May 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesa) 30-count bottles- Lot: 11MY2103 Exp. 11/30/22 Lot: 05JA2106 Exp. 6/30/22 b) 90-count bottles- Lot: 20MY2115 Exp. 11/30/22 Lot: 22JU2118 Exp. 12/31/22 Lot: 29JY2113 Exp. 12/31/22 Lot: 13SE2113 Exp. 2/28/23 Lot: 05JA2106 Exp. 6/30/22
NDC72189-012, 72189-098, 72189-129, 72189-139, 72189-167
Quantity recalled81 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0971-2022
FDA event ID
90161
Recalling firm
Direct Rx, Dawsonville, GA
Manufacturer
Direct_Rx
Classification
Class II
Status
Terminated
Recall initiated
5 May 2022
FDA classified
27 May 2022
Reported
8 Jun 2022
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

5 May 2022Recall initiated by company
27 May 2022Classified by FDA+22 days
8 Jun 2022Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Losartan Pot./HCTZ 100/12.5 mg Packaged and Distributed By: Direct Rx Dawsonville, GA 30534 Mfg For: Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 a) 30 Tabs NDC 72189-167-30; b) 90 Tabs NDC 72189-167-90

Where it was distributed

AL, GA, FL, LA

AlabamaFloridaGeorgiaLouisiana

Questions about this recall

Why was it recalled?

CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits

Which lots are affected?

a) 30-count bottles- Lot: 11MY2103 Exp. 11/30/22 Lot: 05JA2106 Exp. 6/30/22 b) 90-count bottles- Lot: 20MY2115 Exp. 11/30/22 Lot: 22JU2118 Exp. 12/31/22 Lot: 29JY2113 Exp. 12/31/22 Lot: 13SE2113 Exp. 2/28/23 Lot: 05JA2106 Exp. 6/30/22

Where was it sold?

AL, GA, FL, LA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Direct Rx

All 37

Other Losartan recalls

All 97
ReportedClassRecallCompanyReasonWhere
DrugCLASS IILosartan Potassium and Hydrochlorothiazide Tablets recalledLosartan Potassium And HydrochlorothiazideMacleods Pharma USAForeign MaterialNationwide
DrugCLASS IILosartan Potassium Tablets, USP, 25 mg recalled by Strides PharmaLosartan PotassiumStrides PharmaForeign MaterialNationwide
DrugCLASS IILosartan potassium & Hydrochlorothiazide Tablets 100 mg/25 recalledLosartan Potassium And HydrochlorothiazideMacleods Pharma UsaPotency & AssayNationwide
DrugCLASS IILosartan Potassium Tablets, USP 25 mg recalled by PD-Rx PharmaceuticalsLosartan PotassiumPD-Rx PharmaceuticalsPotency & AssayNationwide
DrugCLASS IILosartan Potassium Tablets, USP 100 mg recalled by PD-Rx PharmaceuticalsLosartan PotassiumPD-Rx PharmaceuticalsPotency & AssayNationwide